AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35222690 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-slicer software-assisted endoscopic treatment
Number of subjects: 120
Study 35222690 — intervention group
Group type: COMPARATOR
Intervention: Traditional imaging positioning craniotomy (Control)
Number of subjects: 120
Study 35469232 — intervention group
Group type: EXPERIMENTAL
Intervention: long‐handled Kaiselu +1 cathartic intervention (Group A)
Number of subjects: 61
Study 35469232 — intervention group
Group type: EXPERIMENTAL
Intervention: long‐handled Kaiselu +2 cathartic intervention (Group B)
Number of subjects: 61
Study 35469232 — intervention group
Group type: EXPERIMENTAL
Intervention: enema plus one cathartic intervention (Group C)
Number of subjects: 61
Study 34693691 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexidol
Number of subjects: 0
Study 34693691 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamberin
Number of subjects: 0
Study 34693691 — intervention group
Group type: EXPERIMENTAL
Intervention: Emoxypine
Number of subjects: 0
Study 34693691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32618242 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass Drug Administration (MDA)
Number of subjects: 1880
Study 32618242 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal Mass Drug Administration (fMDA)
Number of subjects: 1880
Study 32618242 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (Control)
Number of subjects: 1880
Study 32618242 — intervention group
Group type: EXPERIMENTAL
Intervention: MDA and fMDA
Number of subjects: 1880
Study 32618242 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-wide sensitization program
Number of subjects: 1880
Study 35833091 — intervention group
Group type: COMPARATOR
Intervention: Fascia Iliaca Block (FIB)
Number of subjects: 50
Study 35833091 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmuscular Quadratus Lumborum Block (TQLB)
Number of subjects: 50
Study 32405121 — intervention group
Group type: EXPERIMENTAL
Intervention: Moral reasoning exercise prior to choice task
Number of subjects: 0
Study 32405121 — intervention group
Group type: COMPARATOR
Intervention: Control group (no moral reasoning exercise)
Number of subjects: 0
Study 32951293 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin and paclitaxel
Number of subjects: 529
Study 32951293 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 529
Study 32102782 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention practices with electronic algorithm, staff educational training, and patient awareness materials.
Number of subjects: 24473
Study 32102782 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention practices
Number of subjects: 24473
Study 32102782 — intervention group
Group type: COMPARATOR
Intervention: Control practices
Number of subjects: 24473
Study 34331505 — intervention group
Group type: EXPERIMENTAL
Intervention: PRESERFLO™ MicroShunt
Number of subjects: 52
Study 34331505 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 52
Study 34331505 — intervention group
Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 52
Study 34037760 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/velpatasvir (SOF/VEL) plus national standard of care
Number of subjects: 80
Study 34037760 — intervention group
Group type: COMPARATOR
Intervention: National standard of care alone
Number of subjects: 80
Study 34918971 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-Low-Carbohydrate Ketogenic Diet (VLCKD) for 140 days
Number of subjects: 0
Study 32424833 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic Restorative Treatment and Hall crown approaches (ARTs)
Number of subjects: 65
Study 32424833 — intervention group
Group type: COMPARATOR
Intervention: Dental general anaesthesia (DGA)
Number of subjects: 65
Study 35599912 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-sleep protein (PRO) supplement containing 40 g of casein protein (n=10)
Number of subjects: 18
Study 35599912 — intervention group
Group type: COMPARATOR
Intervention: Non-caloric, flavor matched placebo (PLA) (n=8)
Number of subjects: 18
Study 33772220 — intervention group
Group type: EXPERIMENTAL
Intervention: NBS plus exome sequencing (ES)
Number of subjects: 159
Study 33772220 — intervention group
Group type: COMPARATOR
Intervention: Conventional NBS
Number of subjects: 159
Study 32441675 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-provided education about chemotherapy-associated taste disorders
Number of subjects: 53
Study 32441675 — intervention group
Group type: COMPARATOR
Intervention: Control group (no education)
Number of subjects: 53
Study 35251294 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib in combination with other drugs
Number of subjects: 43
Study 35251294 — intervention group
Group type: COMPARATOR
Intervention: Anlotinib monotherapy
Number of subjects: 43
Study 33146693 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification (CBM)
Number of subjects: 300
Study 33146693 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 300
Study 35662322 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 12
Study 35662322 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 12
Study 35662322 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline
Number of subjects: 12
Study 35662322 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 12
Study 35662322 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 12
Study 34154552 — intervention group
Group type: EXPERIMENTAL
Intervention: Asdzáán Be'eena' program (11-session intervention)
Number of subjects: 410
Study 34154552 — intervention group
Group type: COMPARATOR
Intervention: Mailed non‐monetary incentives (control arm)
Number of subjects: 410
Study 34487909 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotator Cuff Tear Group (RCT)
Number of subjects: 49
Study 34487909 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 49
Study 34487909 — intervention group
Group type: EXPERIMENTAL
Intervention: Both GTA and CSA values
Number of subjects: 49
Study 34261764 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstract with spin
Number of subjects: 128
Study 34261764 — intervention group
Group type: COMPARATOR
Intervention: Abstract without spin
Number of subjects: 128
Study 33009865 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation technique for designing definitive crowns
Number of subjects: 24
Study 33009865 — intervention group
Group type: EXPERIMENTAL
Intervention: Library technique for designing definitive crowns
Number of subjects: 24
Study 33009865 — intervention group
Group type: COMPARATOR
Intervention: Interim crowns
Number of subjects: 24
Study 33067215 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric assembly A1
Number of subjects: 20
Study 33067215 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric assembly B1
Number of subjects: 20
Study 33067215 — intervention group
Group type: COMPARATOR
Intervention: Nonchimeric assembly C1
Number of subjects: 20
Study 35901983 — intervention group
Group type: COMPARATOR
Intervention: Placebo delivery (0 mg)
Number of subjects: 45
Study 35901983 — intervention group
Group type: COMPARATOR
Intervention: Steady-state delivery (2 mg)
Number of subjects: 45
Study 35901983 — intervention group
Group type: COMPARATOR
Intervention: Random nicotine delivery (RND) (0 mg or 4 mg)
Number of subjects: 45
Study 34145680 — intervention group
Group type: EXPERIMENTAL
Intervention: Eligible for any study (415 patients, 31.8%)
Number of subjects: 1305
Study 34145680 — intervention group
Group type: EXPERIMENTAL
Intervention: IABP-SHOCK II trial eligibility (26.9%)
Number of subjects: 1305
Study 34145680 — intervention group
Group type: EXPERIMENTAL
Intervention: CS caused by acute myocardial infarction (AMI)
Number of subjects: 1305
Study 34145680 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall trials
Number of subjects: 1305
Study 32211998 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (progressive upright aerobic and resistance exercises targeting the trunk and major muscle groups)
Number of subjects: 40
Study 32211998 — intervention group
Group type: COMPARATOR
Intervention: Control (motor control training and manual therapy)
Number of subjects: 40
Study 34297099 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-proactive TDM algorithm incorporating POCT
Number of subjects: 187
Study 34297099 — intervention group
Group type: COMPARATOR
Intervention: Reactive TDM
Number of subjects: 187
Study 34157312 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 µg/d Cu-IUS
Number of subjects: 29
Study 34157312 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 µg/d Cu-IUS
Number of subjects: 29
Study 34157312 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 µg/d Cu-IUS
Number of subjects: 29
Study 34864911 — intervention group
Group type: EXPERIMENTAL
Intervention: UPA 15 mg QD monotherapy
Number of subjects: 1916
Study 34864911 — intervention group
Group type: EXPERIMENTAL
Intervention: UPA 30 mg QD monotherapy
Number of subjects: 1916
Study 34864911 — intervention group
Group type: EXPERIMENTAL
Intervention: UPA 15 mg QD combination therapy
Number of subjects: 1916
Study 34864911 — intervention group
Group type: EXPERIMENTAL
Intervention: UPA 30 mg QD combination therapy
Number of subjects: 1916
Study 34864911 — intervention group
Group type: COMPARATOR
Intervention: UPA monotherapy
Number of subjects: 1916
Study 34864911 — intervention group
Group type: COMPARATOR
Intervention: UPA combination therapy
Number of subjects: 1916
Study 33607215 — intervention group
Group type: EXPERIMENTAL
Intervention: GB21 acupressure
Number of subjects: 174
Study 33607215 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 174
Study 33607215 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 174
Study 35978405 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-minute motor coordination intervention
Number of subjects: 103
Study 35978405 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control condition
Number of subjects: 103
Study 35278356 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by chemotherapy plus durvalumab and tremelimumab
Number of subjects: 124
Study 35278356 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus durvalumab
Number of subjects: 124
Study 35278356 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus durvalumab and tremelimumab
Number of subjects: 124
Study 35278356 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all groups)
Number of subjects: 124
Study 35278356 — intervention group
Group type: COMPARATOR
Intervention: Adverse events
Number of subjects: 124
Study 35639376 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait plus HVLT‐R decline
Number of subjects: 16855
Study 35639376 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait plus 3MS decline
Number of subjects: 16855
Study 35639376 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait plus COWAT‐F decline
Number of subjects: 16855
Study 35639376 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait plus SDMT decline
Number of subjects: 16855
Study 35639376 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual decliners (gait and cognitive decline)
Number of subjects: 16855
Study 33271042 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT)
Number of subjects: 86
Study 33271042 — intervention group
Group type: COMPARATOR
Intervention: Computerized Attention Training (CT)
Number of subjects: 86
Study 36321352 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium chloride (KCl) sustained-release tablets, oral dose of 6 g under fasting conditions
Number of subjects: 0
Study 36321352 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium chloride (KCl) sustained-release tablets, oral dose of 6 g under different dietary arrangements
Number of subjects: 0
Study 33632127 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) - Supine position for 2 hours, then semi-seated position with bed angle increased to 45° over 4 hours.
Number of subjects: 72
Study 33632127 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - Remained in supine position for 6 hours.
Number of subjects: 72
Study 33422013 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care model for chronic condition management (social, behavioral, cognitive interventions)
Number of subjects: 0
Study 33422013 — intervention group
Group type: COMPARATOR
Intervention: General intervention (control arm)
Number of subjects: 0
Study 34274940 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine plus rituximab (BR)
Number of subjects: 537
Study 34274940 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 537
Study 32383050 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (15 mg per day)
Number of subjects: 77
Study 32383050 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin (100 mg per day)
Number of subjects: 77
Study 33919513 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee consumption
Number of subjects: 2201
Study 33919513 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma folate
Number of subjects: 2201
Study 33919513 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Number of subjects: 2201
Study 32238507 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based cognitive behavioral therapy (T-CBT)
Number of subjects: 72
Study 32238507 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 72
Study 34858310 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral tDCS
Number of subjects: 40
Study 34858310 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral tDCS
Number of subjects: 40
Study 34858310 — intervention group
Group type: COMPARATOR
Intervention: Placebo tDCS (sham)
Number of subjects: 40
Study 34858310 — intervention group
Group type: EXPERIMENTAL
Intervention: Training alone
Number of subjects: 40
Study 34858310 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of training and tDCS
Number of subjects: 40
Study 34867115 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligent training system, twice a day, 20 minutes each time.
Number of subjects: 48
Study 34867115 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation training (control group).
Number of subjects: 48
Study 33048906 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led consultations (3 sessions within 2 months)
Number of subjects: 224
Study 33048906 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 224
Study 35872355 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% HP + blue LED
Number of subjects: 30
Study 35872355 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% HP + violet LED
Number of subjects: 30
Study 35872355 — intervention group
Group type: COMPARATOR
Intervention: 35% HP
Number of subjects: 30
Study 35857752 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC) 2 g daily
Number of subjects: 84
Study 33899191 — intervention group
Group type: EXPERIMENTAL
Intervention: 3g of magnesium sulfate in 100mL of glucose solution (Group A)
Number of subjects: 103
Study 33899191 — intervention group
Group type: COMPARATOR
Intervention: 100 mL of glucose solution (Group B)
Number of subjects: 103
Study 35551291 — intervention group
Group type: EXPERIMENTAL
Intervention: PGDM1400, PGT121, and VRC07-523LS (20 mg kg−1 each)
Number of subjects: 5
Study 35551291 — intervention group
Group type: EXPERIMENTAL
Intervention: PGDM1400, PGT121, and VRC07-523LS
Number of subjects: 5
Study 35551291 — intervention group
Group type: EXPERIMENTAL
Intervention: PGDM1400 and PGT121
Number of subjects: 5
Study 35551291 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Number of subjects: 5
Study 33309151 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions improving life-expectancy
Number of subjects: 80
Study 33309151 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions improving quality-of-life
Number of subjects: 80
Study 33309151 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions involving socioeconomic groups
Number of subjects: 80
Study 33309151 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions involving neutrally labelled groups
Number of subjects: 80
Study 32074953 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (ET) - 3 times/week on a treadmill for 8 weeks
Number of subjects: 57
Study 32074953 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit resistance training (RT) - equal number of circuit weight training sessions for 8 weeks
Number of subjects: 57
Study 32074953 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising control group
Number of subjects: 57
Study 35751528 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg b.i.d. plus aspirin 100 mg o.d.
Number of subjects: 27495
Study 35751528 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100 mg o.d.
Number of subjects: 27495
Study 33029705 — intervention group
Group type: EXPERIMENTAL
Intervention: Folinic acid (2 mg/kg up to 50 mg per day)
Number of subjects: 55
Study 33029705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 32911530 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric exercises
Number of subjects: 23
Study 32911530 — intervention group
Group type: COMPARATOR
Intervention: Strength exercises
Number of subjects: 23
Study 35868342 — intervention group
Group type: EXPERIMENTAL
Intervention: Pay-it-forward intervention (free influenza vaccine and opportunity to donate)
Number of subjects: 300
Study 35868342 — intervention group
Group type: EXPERIMENTAL
Intervention: Pay-it-forward intervention
Number of subjects: 300
Study 35868342 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care user-paid vaccination
Number of subjects: 300
Study 33814451 — intervention group
Group type: EXPERIMENTAL
Intervention: Go/No-Go task measuring commission errors (CE) and intraindividual variability of reaction time (CV) over a 90-second test.
Number of subjects: 110
Study 33814451 — intervention group
Group type: COMPARATOR
Intervention: Go/No-Go task measuring commission errors (CE) and intraindividual variability of reaction time (CV).
Number of subjects: 110
Study 35678327 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoxia group (NG) with PaO2 between ≥100 and <180 mmHg and at least 40% FiO2 mechanical ventilation (MV)
Number of subjects: 100
Study 35678327 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoxia group (NG)
Number of subjects: 100
Study 35678327 — intervention group
Group type: COMPARATOR
Intervention: Hyperoxia group (HG) with PaO2 ≥180 mmHg and 100% FiO2 MV
Number of subjects: 100
Study 33514604 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry flocked swab (DF)
Number of subjects: 600
Study 33514604 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet dacron swab (WD)
Number of subjects: 600
Study 33514604 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine sample (Colli-Pee device)
Number of subjects: 600
Study 33514604 — intervention group
Group type: EXPERIMENTAL
Intervention: Qvintip (QT)
Number of subjects: 600
Study 33514604 — intervention group
Group type: EXPERIMENTAL
Intervention: HerSwab (HS)
Number of subjects: 600
Study 32933577 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced support from a physiotherapist (PT group)
Number of subjects: 190
Study 32933577 — intervention group
Group type: COMPARATOR
Intervention: Ordinary PAP treatment at the health care centre (HCC group)
Number of subjects: 190
Study 32933577 — intervention group
Group type: EXPERIMENTAL
Intervention: PT group
Number of subjects: 190
Study 32933577 — intervention group
Group type: COMPARATOR
Intervention: HCC group
Number of subjects: 190
Study 32933577 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 190
Study 35576638 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 540
Study 35576638 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/kg magnolol (M300)
Number of subjects: 540
Study 35576638 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/kg honokiol (H300)
Number of subjects: 540
Study 35576638 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/kg total phenols with a magnolol/honokiol ratio of 2:1 (M200H100)
Number of subjects: 540
Study 35576638 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/kg total phenols with a magnolol/honokiol ratio of 1:2 (M100H200)
Number of subjects: 540
Study 35576638 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/kg total phenols with a magnolol/honokiol ratio of 1:1 (M150H150)
Number of subjects: 540
Study 34704866 — intervention group
Group type: EXPERIMENTAL
Intervention: MindfulGarden (MG), a digital calming device, used during morning and evening care for 3 days, followed by exposure with verbal prompting on Day 4.
Number of subjects: 13
Study 34704866 — intervention group
Group type: COMPARATOR
Intervention: Usual care only (control group).
Number of subjects: 13
Study 32712801 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 720
Study 32712801 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Food Intake Index (HFII)
Number of subjects: 720
Study 32712801 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycemic health
Number of subjects: 720
Study 32712801 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) and Healthy Food Intake Index (HFII)
Number of subjects: 720
Study 35111716 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory priming
Number of subjects: 9811
Study 35111716 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual priming
Number of subjects: 9811
Study 35111716 — intervention group
Group type: EXPERIMENTAL
Intervention: Both olfactory and visual priming
Number of subjects: 9811
Study 35111716 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 9811
Study 35845514 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg esketamine, i.v.
Number of subjects: 120
Study 35845514 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg esketamine, i.v.
Number of subjects: 120
Study 35845514 — intervention group
Group type: COMPARATOR
Intervention: Regular anesthesia model (Group A, control)
Number of subjects: 120
Study 33420781 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety guidewire present (Group 1)
Number of subjects: 320
Study 33420781 — intervention group
Group type: COMPARATOR
Intervention: No safety guidewire (Group 2)
Number of subjects: 320